The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a ...

As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are ...

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...

The deal will give Lyell a dual-targeting CAR-T candidate for blood cancers. Relatedly, Lyell will also end development of ...

An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...

Xavier, who leads biotech venture investing for the big drugmaker, expects an uptick in IPOs as well as renewed interest in ...

Septerna upped the size of its offering twice before pricing a stock sale that raised funds for its lead candidate, a ...

Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...

We’re investing in this future by working with Rancho on the next generation of our database. We’re creating a pathway to ...

Early data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such ...

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance ...